Skip to main content
Chandler Park, MD, Oncology, Corydon, IN

ChandlerHParkMDFACP

Oncology • Corydon, IN

Gastrointestinal Cancer, Genitourinary Oncology, Hematologic Oncology, Thoracic Cancer

•Advisory Dean University of Louisville School of Medicine •President Kentucky Society of Clinical Oncology (ASCO chapter) •Principal Investigator for Cancer Clinical Trials •3X NEJM Published Author •ASCO CME Faculty •ABIM Medical Oncology Exam Committee Task Force Advisor Neil Love, MedPro, OncLive •Cancer Physician serving patients in the greater Louisville, Kentucky area

Join to view full profile

Dr. Park is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Park's full profile

Already have an account?

  • Office

    1263 Hospital Dr NW
    Ste 110
    Corydon, IN 47112
    Phone+1 812-734-0912
    Fax+1 502-629-2055

Summary

  • Chandler Park is an American physician, media correspondent, and clinical researcher. Park has been very fortunate to be published in the New England Journal of Medicine three times as a Principal Investigator and Author for original research in genitourinary cancer.

    He has a passion for medical education. At the University of Louisville, he works as an Advisory Dean to help medical students during their medical school journey.

    In terms of oncology education, Park hosts continuing medical education meetings to update physicians throughout the country by hosting CME programs in Nashville, Cleveland, Seattle, and Denver.

    Park contributes regularly as an expert physician for popular newspapers and magazines such as Newsweek, Reader's Digest,U.S. News & World Report and Medscape. He is also the founder of Cancervisit.com a medical information company dedicated to helping cancer patients and their families.

    Park is also a medical school professor at the University of Louisville School of Medicine. He is triple-board-certified in internal medicine, hematology and oncology. In 2016, he was recognized nationally by his physician colleagues as a distinguished fellow of the American College of Physicians (FACP) for providing outstanding patient care and significant medical research contributions.

    Park is a practicing hematologist and oncologist that has won many patient satisfaction awards including Press Ganey.

    He has also served as an assistant professor, attending hospitalist physician, and Chief Resident at Indiana University Health affiliated hospitals. He is an accomplished medical researcher having written many scientific research articles and manuscripts in leading medical journals.

    His cancer research has been presented at leading cancer society meetings including his research on PET/CT and regional brain metabolic changes associated with depression in breast cancer patients at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting.

    • OncLive interviews Dr. Park on Biomarker testing/PSMA PET use in Prostate Cancer

    Chandler Park, MD, MSc, FACP, co-director, discusses emerging field of genetic testing, PSMA PET scan, and radioligand treatment in patients w/ prostate cancer.

    Dr. Chandler Park teaching case: 51-Year-Old Man with Renal Cell Carcinoma

    Chandler Park, MD: My name is Dr. Chandler Park. I'm a oncologist at Norton Cancer Institute. Today, we have a very interesting case on renal cell cancer.

    Home - Chandler Park, M.D.

    As someone that has helped select residents in residency programs, I have seen some common mistakes that can be avoided. 1. Not knowing where you stand You need

Education & Training

  • UPMC Medical Education
    UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2013 - 2014
  • West Virginia University
    West Virginia UniversityFellowship, Hematology and Medical Oncology, 2011 - 2014
  • Indiana University School of Medicine
    Indiana University School of MedicineResidency, Internal Medicine, 2009 - 2011
  • Indiana University School of Medicine
    Indiana University School of MedicineResidency, Radiology-Diagnostic, 2008 - 2009
  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationInternship, Internal Medicine, 2007 - 2008
  • University of Louisville School of Medicine
    University of Louisville School of MedicineClass of 2007
  • University of Illinois at Urbana-Champaign
    University of Illinois at Urbana-ChampaignB.S., Biomedical Engineering & Biochemistry

Certifications & Licensure

  • IN State Medical License
    IN State Medical License 2009 - 2025
  • KY State Medical License
    KY State Medical License 2016 - 2025
  • WV State Medical License
    WV State Medical License 2013 - 2017
  • OH State Medical License
    OH State Medical License 2007 - 2011
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America’s Top Doctor Castle Connolly Top Doctors, 2019-2023
  • America’s Top Oncologist Castle Connolly, 2019-2023
  • CME Faculty ASCO (American Society of Clinical Oncology), 2018-2022
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic ur...  
    Petros Grivas, Damien Pouessel, Chandler H. Park, Philippe Barthelemy, Manojkumar Bupathi, Daniel P. Petrylak, Neeraj Agarwal et al, Journal of Clinical Oncology 2023 41:6_suppl, 518-518, 2/23/2023
  • Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (m...  
    Daniel P. Petrylak, Scott T. Tagawa, Rohit K. Jain, Chandler Park et al, Journal of Clinical Oncology 2023 41:6_suppl, 520-520, 2/22/2023
  • Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer  
    Matthew R. Smith, M.D., Ph.D., Maha Hussain, M.D., Fred Saad, M.D., Chandler H. Park, M.D., Boris Alekseev, M.D., Hiroyoshi Suzuki, M.D., Ph.D., Bertrand Tombal, M.D.,..., New England Journal of Medicine, 2/17/2022
  • Join now to see all

Lectures

  • PET/CT and Regional Brain Metabolic Changes Associated with Depression in Metastatic Breast Cancer 
    1/1/2016
  • Sorafenib and thyroid cancer 
    1/1/2014
  • Sunitinib As the "Second Hit" In Acute Esophageal Necrosis 
    1/1/2014
  • Join now to see all

Other

Authored Content

  • 2020 Bladder Cancer Review with Dr. Petros Grivas: What Every Physician Should KnowDecember 2020
  • ESMO 2020: What's New with Prostate Cancer TreatmentOctober 2020
  • ESMO 2020: What Every Physician Should KnowSeptember 2020
  • 2019 Breast Cancer Review: What Every Physician Should KnowJanuary 2020
  • 2019 Breast Cancer Review: What Every Physician Should KnowJanuary 2020
  • The Rise and Cost of CAR-T Cell Treatment: What Every Physician Should KnowDecember 2019
  • The Rise and Cost of CAR-T Cell Treatment: What Every Physician Should KnowDecember 2019
  • Must-Read Updates in CLL, AML, and Non-Hodgkin's Research from ASH 2019December 2019
  • Must-Read Updates in CLL, AML, and NHL Research from ASH 2019December 2019
  • ASH 2018: Research That Will Make a Difference for Tomorrow's OncologistDecember 2018
  • ASH 2018: Research That Will Make a Difference for Tomorrow's OncologistDecember 2018
  • ASCO CME Medical Oncology Question Writer for May 20185/3/2018
  • ASCO CME Medical Oncology Question Writer for January 20181/3/2018
  • Practice-Changing Update for Newly Diagnosed Stage III or Stage IV Hodgkin’s Lymphoma PatientsDecember 2017
  • Practice-Changing Update for Newly Diagnosed Stage III or Stage IV Hodgkin’s Lymphoma PatientsDecember 2017
  • The Hidden Curriculum: How to Avoid Being Labeled a “Problem Resident”August 2017
  • The Hidden Curriculum: How to Avoid Being Labeled a “Problem Resident”August 2017
  • The Hidden Curriculum: How to Avoid Being Labeled a “Problem Resident”August 2017
  • Red Flags of Residency Personal StatementsAugust 2017
  • Red Flags of Residency Personal StatementsAugust 2017
  • Red Flags of Residency Personal StatementsAugust 2017
  • Join now to see all

Press Mentions

  • Dr. Park Considers Long-Term Data for Frontline Metastatic ccRCC Treatment
    Dr. Park Considers Long-Term Data for Frontline Metastatic ccRCC TreatmentNovember 24th, 2023
  • Future Outlook of Kidney Cancer Treatment
    Future Outlook of Kidney Cancer TreatmentOctober 25th, 2023
  • Advice for Patients with Advanced Renal Cell Carcinoma
    Advice for Patients with Advanced Renal Cell CarcinomaOctober 25th, 2023
  • Join now to see all

Committees

  • Advisory Board and Selection Committee Member, Giants of Cancer Care 2019 - Present
  • Continuing Medical Education Committee, American Society of Clinical Oncology 2018 - Present
  • Board Member, Leukemia and Lymphoma Society (LLS) Executive Board for Kentucky and Indiana 2016 - Present

Research History

  • Principal InvestigaorPrincipal Investigator for clinical trials in genitourinary cancers that include kidney, bladder, and prostate cancer.2019 - Present

Professional Memberships

External Links

Dr. Chandler Park, Dr. Chandler Park, MD, Dr. C Park, Dr. Chandler H Park